



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MES-SA/Dx5 Cell Lysate: sc-2284

BACKGROUND

Santa Cruz Biotechnology, Inc. offers whole cell lysates for use in combination with research antibodies as Western Blotting controls. MES-SA/Dx5 Cell Lysate is derived from a multi drug-resistant human uterine sarcoma cell line. MES-SA/Dx5 lineage originates from the human uterine sarcoma cell line MES-SA. MES-SA epithelial cell lineage originates from a tumor identified within a 56-year-old caucasian female hysterectomy patient in 1980. The Dx5 variant of MES-SA exhibits ~100-fold doxorubicin resistance and ~30 hour doubling time. MES-SA/Dx5 cell lysate is derived from cultured MES-SA/Dx-5 cells using a preparation method (RIPA Lysis Buffer System (sc-24948)), that ensures protein integrity and lot-to-lot reproducibility. Whole cell lysates are tested by Western Blotting in order to ensure each preparation contains a consistent concentration, and assortment of proteins.

REFERENCES

1. Wang, E., et al. 2000. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. *J. Cell. Physiol.* 184: 263-274.
2. Wesolowska, O., et al. 2005. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. *Anticancer Res.* 25: 383-389.
3. Hung, T.H., et al. 2014. FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells. *Int. J. Biochem. Cell. Biol.* 53: 55-65.
4. Pósa, S.P., et al. 2022. Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines. *Bioorg. Med. Chem.* 67: 116855.

SOURCE

MES-SA/Dx5 lineage originates from the MES-SA cell line.

Organism: *Homo sapiens* (human)
 Source: Caucasian female
 Tissue of Origin: Uterus/hysterectomy/tumor
 Cell Type: Epithelial
 Growth Properties: Adherent

PRODUCT

Each vial contains 500 µg protein in 200 µl of an SDS-PAGE Western Blotting buffer, which consists of 100 µl RIPA Lysis Buffer and 100 µl Electrophoresis Buffer, 2X.

APPLICATIONS

MES-SA/Dx5 Cell Lysate is provided as a Western Blotting positive control. Recommended use is 50 µg (20 µl) per lane. Sample vial should be boiled once prior to use.

STORAGE

Store at -20° C; stable for one year from the date of shipment. Non-hazardous. No MSDS required. Minimize repeated freezing and thawing.

PREPARATION METHOD

MES-SA/Dx5 cells are cultured with appropriate media conditions and allowed to reach a confluency of 75%. Cells are lysed using the RIPA Lysis Buffer System (sc-24948). BCA Protein Assay is used to determine the total protein concentration. The lysate is adjusted to contain 500 µg of total cellular protein in 100 µl before adding an equal volume of Electrophoresis Sample Buffer, 2X (sc-24945). Final concentration of product is 500 µg total protein in a final volume of 200 µl.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.